We are developing immunotherapies that have the potential to transform the lives of patients with life threatening and debilitating conditions. Atara Biotherapeutics’ development programs leverage the fundamental benefits of our allogeneic cytotoxic T lymphocyte (CTL) immunotherapy platform, with broad applicability over a variety of disease states, including cancers, certain autoimmune diseases, and severe viral infections.

As pioneers in cellular immunotherapy, we are interested in exploring ways, through our internal development teams and external partnerships, to further the potential applications of our therapeutic platform through:

  • Combination therapy with CTLs and other agents, where the science indicates possibilities for therapeutic synergies
  • Next generation and complimentary technologies in cellular immunotherapy
  • Biomarkers to facilitate patient selection and track treatment effect
  • Integrating genetic engineering with our allogeneic platform “backbone” for select conditions

We welcome collaboration and licensing opportunities to broadly explore the potential of our technologies, and to help effectively bring transformational therapies to patients. If you would like to discuss partnering with Atara Biotherapeutics, please contact: